News

Foundery Announces Initial Close of Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies

August 22, 2023
Foundery, a biotechnology venture studio focused on transla6ng immunology discoveries into drug candidates, today announced an initial close of its inaugural fund, Foundery I, LP (“Foundery Fund I”), with total capital commitments and contributed assets as of the closing equal to $29.6 million.

MindRhythm Announces Publication in JAMA Network Open of Novel Headset for Return to Play Decisions in Concussion

August 11, 2023
Novel, noninvasive, headset detects a newly discovered biometric that allows for objective identification of concussion and recovery. “Concussion is common in sports and returning to play before recovery can cause long-term neurological impairment or permanent brain injury,” said Cathra Halabi, MD...

Philanthropic endowments at universities can offer a way out of biotech’s Valley of Death

August 11, 2023
"A new idea now taking hold in academia offers the promise of a path out of the Valley of Death: Universities, whose labs are home to so many of these potentially life-changing discoveries, should raise a philanthropic endowment and use the money to fund the work of the scientists to advance their...

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

August 08, 2023
Ikena Oncology, a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.

Scalable Care Inc signs landmark license agreement with UCSF to commercialize evidence-based mental health resources

July 19, 2023
Scalable Care Inc signs an exclusive worldwide licensing agreement with UCSF to commercialize evidence-based digital mental health therapies that help teenagers and young adults manage emotions, cope with trauma, resolve interpersonal conflicts, and learn self-reflection using conversational AI and...

BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data

June 29, 2023
BeeKeeperAI, Inc., a pioneer in zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), today announced that it has closed $12.1 million in Series A financing. The round was led by Santé Ventures, with participation from the Icahn School of Medicine at...

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

June 23, 2023
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

MindRhythm Announces First Patient Enrolled in Pivotal Study of Novel Harmony™ Device for Rapid Detection of Stroke

June 22, 2023
MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announced that the first patient has been enrolled in the pivotal portion of its HeadPulse for Ischemic Stroke Detection Prehospital Study (EPISODE-VS). EPISODE-VS is designed to validate that...

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

June 20, 2023
Congratulations to Charles Chiu, Joe DeRisi, Michael Wilson and the Delve Bio team on their $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II and joined by Section 32 and Google Ventures!  UCSF is happy to partner with this talented and experienced team of scientists and...

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epileps

June 20, 2023
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of new data from the open-label, single-arm, starting dose-level of its ongoing Phase I/II clinical trial of a one-time dose...

Pages